Promedius wins nod for AI-powered osteoporosis screening solution

Promedius, a Korean medical AI company, announced Thursday that it has received Korean regulatory approval for PROS CXR: OSTEO, a deep learning screening solution that uses chest X-ray images to identify patients suspected of having osteoporosis.

PROS CXR: OSTEO was designated as the first innovative medical device in the field of osteoporosis by the Ministry of Food and Drug Safety in November last year. Promedius plans to accelerate its marketing efforts to enter the domestic medical field and expand both domestic and international markets.

“By screening osteoporosis patients early and providing them with treatment opportunities, this product will help prevent risks that can lead to fractures,” said David Sunghyun Jung, CEO of Promedius. “We anticipate rapid market entry and sales expansion, having undergone a thorough research and verification process to commercialize the product.”

He added that the company expects to leverage the “New Medical Technology Assessment deferred track” to charge patients for non-reimbursement services starting in the third quarter of this year.